| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:40 | MAYNE PHARMA GROUP LIMITED: Ceasing to be a substantial holder from MUFG | 1 | ASX | ||
| 04:39 | MAYNE PHARMA GROUP LIMITED: Final Director's Interest Notice (x2) | 1 | ASX | ||
| Fr | MAYNE PHARMA GROUP LIMITED: Ceasing to be a substantial holder | 1 | ASX | ||
| 23.02. | MAYNE PHARMA GROUP LIMITED: Proposed issue of securities - MYX | 1 | ASX | ||
| 23.02. | MAYNE PHARMA GROUP LIMITED: Final Director's Interest Notice | - | ASX | ||
| 23.02. | Mayne Pharma Sales Steady, Loss Narrows | 1 | Finance News Network | ||
| MAYNE PHARMA GROUP Aktie jetzt für 0€ handeln | |||||
| 23.02. | Mayne Pharma H1 FY26 slides: margins surge despite flat revenue | 1 | Investing.com | ||
| 22.02. | MAYNE PHARMA GROUP LIMITED: 2026 Half Year Investor Presentation | - | ASX | ||
| 22.02. | MAYNE PHARMA GROUP LIMITED: 2026 Half Year Media Release | - | ASX | ||
| 22.02. | MAYNE PHARMA GROUP LIMITED: Half Yearly Report and Accounts | - | ASX | ||
| 22.02. | MAYNE PHARMA GROUP LIMITED: Mayne Pharma Management Changes | - | ASX | ||
| 19.02. | MAYNE PHARMA GROUP LIMITED: Notification of date for release of 1H26 results | 2 | ASX | ||
| 17.02. | MAYNE PHARMA GROUP LIMITED: MYX to claim against Cosette, Avista & Mr David Burgstahler | - | ASX | ||
| 05.02. | MAYNE PHARMA GROUP LIMITED: Ceasing to be a substantial holder | - | ASX | ||
| 29.01. | MAYNE PHARMA GROUP LIMITED: 2025 AGM Results of Meeting | 3 | ASX | ||
| 28.01. | MAYNE PHARMA GROUP LIMITED: 2025 AGM presentation and business update | - | ASX | ||
| 28.01. | MAYNE PHARMA GROUP LIMITED: 2025 AGM Chair's Address to Shareholders | - | ASX | ||
| 19.01. | MAYNE PHARMA GROUP LIMITED: Ceasing to be a substantial holder | - | ASX | ||
| 18.01. | MAYNE PHARMA GROUP LIMITED: Change in substantial holding | - | ASX | ||
| 15.01. | MAYNE PHARMA GROUP LIMITED: Notice of appeal | - | ASX |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 31,880 | +0,65 % | Novo Nordisk schockt Anleger: Abnehmmittel-Studie enttäuscht - Aktie bricht ein, während Eli Lilly zulegt | Ein Dämpfer für den dänischen Pharmariesen: Die jüngste Studie zum Hoffnungsträger Cagrisema verfehlt die Erwartungen deutlich. Anleger reagieren geschockt. Lachender Dritter ist Eli Lilly. So prognostiziert... ► Artikel lesen | |
| PFIZER | 23,305 | -0,36 % | Pfizer, Astellas Pharma Share Positive Data From Bladder Cancer Trial | NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and Astellas Pharma Inc., Friday announced the positive results from the Phase 3 EV-304 clinical trial for PADCEV in combination with Keytruda in... ► Artikel lesen | |
| MERCK KGAA | 126,25 | +0,48 % | Big Blue IBM, Fastly & Merck KGaA - Was sagen Charts UND Fundamentaldaten wirklich? | ||
| AURORA CANNABIS | 3,160 | -3,66 % | Is Aurora Cannabis Stock Ready to 10X in the Next Pot Boom? | ||
| CANOPY GROWTH | 0,910 | -3,40 % | Is It Time to Dump Your Shares of Canopy Growth?? | ||
| ASTRAZENECA | 174,20 | -1,28 % | UBS stuft ASTRAZENECA auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat das Kursziel für Astrazeneca von 16300 auf 17600 Pence angehoben und die Einstufung auf "Buy" belassen. Astrazeneca stehe zum Ende dieses Jahrzehnts... ► Artikel lesen | |
| TILRAY BRANDS | 6,420 | -3,89 % | MDMA-Herausforderer Bioxyne punktet mit 112% Umsatzplus. Und was macht Tilray? | ||
| VERTEX PHARMACEUTICALS | 415,50 | -1,18 % | Vertex Pharmaceuticals Inc. Reports Rise In Q4 Bottom Line | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Inc. (VRTX) reported earnings for its fourth quarter that Increases, from last yearThe company's earnings came in at $1.191 billion... ► Artikel lesen | |
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | TAAT Global Alternatives Inc (2): TAAT Global CEO Saxon resigns | ||
| CRONOS GROUP | 2,242 | -0,97 % | Cronos Group Inc.: Cronos Group Reports 2025 Fourth Quarter and Full-Year Results | Net revenue in Q4 2025 increased by 47% year-over-year to $44.5 million; Net revenue in FY 2025 increased by 25% year-over-year to $146.6 million Achieved record net revenue in Q4 2025 and FY 2025... ► Artikel lesen | |
| VIATRIS | 12,790 | +1,39 % | Viatris Posts Narrower Loss In Q4; Expects Workforce Reduction Of Up To Approx. 10% | WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS) reported a fourth quarter net loss of $340.1 million or $0.30 per share compared to a loss of $516.5 million or $0.43 per share, prior year. The company... ► Artikel lesen | |
| DIGICANN VENTURES | 0,006 | +9,09 % | XFRA VY3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 1,140 | -5,00 % | Organigram Global Inc: Organigram launches Edison, Boxhot in Australia | ||
| GREEN THUMB INDUSTRIES | 5,335 | -3,87 % | Green Thumb Industries Reports Fourth Quarter and Full Year 2025 Results | CHICAGO and VANCOUVER, British Columbia, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. ("Green Thumb" or the "Company") (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer... ► Artikel lesen | |
| SINOPHARM | 2,329 | +2,69 % | HSI Closes at 26,765, Up 175 pts; HSTI Closes at 5,260, Down 10 pts; HAIDILAO Up over 6%; HSBC HOLDINGS, TINGYI, SINOPHARM, TIME INTERCON, WANGUO GOLD GP Hit New Highs; Market Turnover Rises |